Form 4: Vanda Pharmaceuticals CEO Acquires 10,000 Shares
SEC Form 4 Filing
Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, purchased 10,000 shares of common stock at $4.76 per share on February 28, 2025.
Summary
- On February 28, 2025, Mihael Hristos Polymeropoulos, the President and CEO, Chairman of the Board, and Director of Vanda Pharmaceuticals Inc., acquired 10,000 shares of the company's common stock.
- The shares were purchased at a price of $4.76 per share.
- Following this transaction, Polymeropoulos directly owns 2,361,730 shares of Vanda Pharmaceuticals.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. The CEO's purchase could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.
Positives
- The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's valuation and future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of the transaction: CEO purchased 10,000 shares of VNDA common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.